Metric Finance
LearnFAQ
LearnFAQ

Learn / PRME

NASDAQ: PRME

Prime Medicine (PRME) stock, explained like you're 5

Prime Medicine trades on the Nasdaq under the ticker PRME. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 724 million dollars.

Ticker
PRME
Exchange
Nasdaq
Sector
Healthcare
Industry
Biological Products (No Diagnostic Substances)
Size
Small cap, about 724 million dollars

Is Prime Medicine a small, medium or large cap company?

No. Prime Medicine is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 724 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Prime Medicine makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves PRME stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Prime Drink Group Corp. (PRME.CN) Stock Price, News, Quote & History (Yahoo! Finance Canada)
  • Prime Medicine (NASDAQ:PRME) Stock Jumps 8.5% Time to Buy? (MarketBeat)
  • Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why (TradingView)
  • PRME Surges 15% After Winning Arbitration Against Beam Clears Path To Human Trials For Its Gene Editing Drug (Stocktwits)
  • Prime Medicine, Inc. (PRME) stock price, news, quote and history (Yahoo Finance Australia)

Follow PRME in your daily brief

Each trading day at 5 PM ET we post what happened to Prime Medicine and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow PRME

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Prime Medicine stock

What does Prime Medicine do?

Prime Medicine trades on the Nasdaq under the ticker PRME. It is a small cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 724 million dollars.

What is the ticker symbol for Prime Medicine?

Prime Medicine trades under the ticker PRME on the Nasdaq.

What is Prime Medicine's market cap?

Prime Medicine is a small cap stock with a market cap of about 724 million dollars.

How does Prime Medicine make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves PRME stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow PRME stock every day?

Add PRME to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow PRME daily

A free brief on Prime Medicine and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • ARGX · Argenx SE
  • RVMD · Revolution Medicines
  • BNTX · BioNTech SE
  • EXEL · Exelixis

Similar stocks

  • ARGXArgenx SE
  • RVMDRevolution Medicines
  • BNTXBioNTech SE
  • EXELExelixis

Compare PRME: PRME vs ARGX, PRME vs RVMD, PRME vs BNTX

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed